CN114206939A - 用于lag-3/pd-l1双特异性抗体的施用的剂量方案 - Google Patents

用于lag-3/pd-l1双特异性抗体的施用的剂量方案 Download PDF

Info

Publication number
CN114206939A
CN114206939A CN202080051441.8A CN202080051441A CN114206939A CN 114206939 A CN114206939 A CN 114206939A CN 202080051441 A CN202080051441 A CN 202080051441A CN 114206939 A CN114206939 A CN 114206939A
Authority
CN
China
Prior art keywords
cancer
tumor
patient
treatment
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080051441.8A
Other languages
English (en)
Chinese (zh)
Inventor
米歇尔·莫罗
菲奥纳·杰马斯切夫斯基
丹尼尔·格利登
梁健美
克里斯蒂安·格拉迪纳鲁
克里斯托弗·谢泼德
约瑟芬-比特·霍尔茨
露易丝·凯塔利尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yingwox Pharmaceutical Co ltd
Original Assignee
F Star Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1906807.1A external-priority patent/GB201906807D0/en
Priority claimed from GB201914040A external-priority patent/GB201914040D0/en
Priority claimed from GBGB2000318.2A external-priority patent/GB202000318D0/en
Application filed by F Star Therapeutics Ltd filed Critical F Star Therapeutics Ltd
Publication of CN114206939A publication Critical patent/CN114206939A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080051441.8A 2019-05-14 2020-05-14 用于lag-3/pd-l1双特异性抗体的施用的剂量方案 Pending CN114206939A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1906807.1 2019-05-14
GBGB1906807.1A GB201906807D0 (en) 2019-05-14 2019-05-14 Dosages regimes for the administration of lag-3/pd-l1 bispectic antibody
GB1914040.9 2019-09-30
GB201914040A GB201914040D0 (en) 2019-09-30 2019-09-30 Dosage regimes for the administration of lag-3/pd-l1 bispecific antibody
GBGB2000318.2A GB202000318D0 (en) 2020-01-09 2020-01-09 Dosage regimes for the administration of LAG-3/PD-L1 bispecific antibody
GB2000318.2 2020-01-09
PCT/EP2020/063529 WO2020229626A1 (en) 2019-05-14 2020-05-14 Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody

Publications (1)

Publication Number Publication Date
CN114206939A true CN114206939A (zh) 2022-03-18

Family

ID=70775359

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080051441.8A Pending CN114206939A (zh) 2019-05-14 2020-05-14 用于lag-3/pd-l1双特异性抗体的施用的剂量方案

Country Status (12)

Country Link
US (1) US20220275092A1 (https=)
EP (1) EP3969477A1 (https=)
JP (1) JP2022533578A (https=)
KR (1) KR20220008316A (https=)
CN (1) CN114206939A (https=)
AU (1) AU2020275209A1 (https=)
BR (1) BR112021022831A2 (https=)
CA (1) CA3139003A1 (https=)
IL (1) IL287979A (https=)
MX (1) MX2021013943A (https=)
SG (1) SG11202112136RA (https=)
WO (1) WO2020229626A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201811184UA (en) 2016-06-20 2019-01-30 F Star Beta Ltd Lag -3 binding members
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
ES3044118T3 (en) 2018-07-12 2025-11-26 Invox Pharma Ltd Antibody molecules that bind cd137 and ox40
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
PT3820569T (pt) 2018-07-12 2025-01-14 Invox Pharma Ltd Moléculas de anticorpo que se ligam a pd-l1 e cd137
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
JP7850884B2 (ja) * 2021-03-31 2026-04-24 メルス・ベー・フェー 新規多重特異性抗体
US20240101718A1 (en) * 2022-09-28 2024-03-28 Incyte Corporation Anti-pd-1/lag-3 bispecific antibodies and uses thereof
GB202304278D0 (en) 2023-03-23 2023-05-10 F Star Therapeutics Ltd Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018222711A2 (en) * 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
WO2018222718A1 (en) * 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
CN109563171A (zh) * 2016-06-20 2019-04-02 F星德尔塔有限公司 结合pd-l1和lag-3的结合分子

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109563171A (zh) * 2016-06-20 2019-04-02 F星德尔塔有限公司 结合pd-l1和lag-3的结合分子
WO2018222711A2 (en) * 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
WO2018222718A1 (en) * 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"FS118 First in Human Study in Patients With Advanced Malignancies", Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/record/nct03440437?view=record> *
JACQUELINE等: "Abstract B091:A LAG-3/PD-L1 bispecific antibody inhibody inhibits tumor growth in two syngeneic colon carcinoma models", 《CANCER IMMUNOLOGY RESERACH》, vol. 4, no. 11, pages 091 *

Also Published As

Publication number Publication date
JP2022533578A (ja) 2022-07-25
WO2020229626A1 (en) 2020-11-19
AU2020275209A1 (en) 2021-12-23
MX2021013943A (es) 2022-01-04
US20220275092A1 (en) 2022-09-01
IL287979A (en) 2022-01-01
KR20220008316A (ko) 2022-01-20
EP3969477A1 (en) 2022-03-23
SG11202112136RA (en) 2021-11-29
BR112021022831A2 (pt) 2022-01-18
CA3139003A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
CN114206939A (zh) 用于lag-3/pd-l1双特异性抗体的施用的剂量方案
US11767361B2 (en) Method of treating lung cancer
AU2018287519B2 (en) IL-1beta binding antibodies for use in treating cancer
CN101970499B (zh) 用于肿瘤治疗的单克隆抗体
JP6805428B2 (ja) Ｃｅａｃａｍ１に対するヒト化抗体
AU2018308088B2 (en) Treating cancer by blocking the interaction of TIM-3 and its ligand
WO2017181099A1 (en) Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and mehtods of treatment therewith
JP2020507596A (ja) 膀胱癌の抗ｐｄ−ｌ１抗体治療
JP2020529018A (ja) チェックポイント阻害薬のための予測末梢血バイオマーカー
US20220056123A1 (en) Use of il-1beta binding antibodies
WO2024196952A1 (en) Tumor subtype assessment for cancer therapy
WO2020128637A1 (en) Use of il-1 binding antibodies in the treatment of a msi-h cancer
RU2818587C2 (ru) Режимы дозирования при введении биспецифичного антитела против lag -3/pd-l1
KR20200106921A (ko) 암을 치료하기 위한 방법 및 조합 요법
US20240156908A1 (en) USE OF sEphB4-HSA FUSION PROTEIN AS A FIRST-LINE THERAPY IN CANCER TREATMENT
HK40118859A (zh) 用於治疗肿瘤的抗-cd73、抗-pd-l1抗体和化疗

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240818

Address after: London

Applicant after: Yingwox Pharmaceutical Co.,Ltd.

Country or region after: Britain

Address before: Cambridge County, England

Applicant before: F-star treatment Co.,Ltd.

Country or region before: Britain

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20220318